DNA X, Inc.(SONM)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,574 of 2,884 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
SONM Stock Analysis & AI Quality Score
Data updated 2026-08-18AI stock analysis and institutional research for DNA X, Inc. (SONM), a Technology sector company. 13F Pro's AI-powered ranking engine scores SONM at 26.5/100 on a 32-signal composite quality model, placing it at rank #2,574 of 2,884 stocks — the bottom half of the AI-ranked universe. SONM scores in the top quartile across balance sheet strength (94.5). Areas of concern include earnings quality (1.2) and revenue growth (3.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 33.1/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of SONM by reported 13-F value include C2C Wealth Management, BlackRock, CITADEL ADVISORS, based on the most recent SEC filings. SONM trades on the Nasdaq exchange and files with the SEC under CIK 1178697. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SONM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DNA X, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-1.2M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
+38.6% YoYOperating Income
-74.4% YoYEPS (Diluted)
+77.7% YoYTotal Assets
+10.5% YoYTotal Debt
Op. Cash Flow
-177.2% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | $58.3M -37.7% | $93.6M +34.1% | $69.8M +28.0% | $54.6M -14.7% | $64.0M |
| Net Income | $-20.7M +38.6% | $-33.6M -37286.7% | $-90.0K +99.4% | $-14.1M +63.5% | $-38.6M -29.0% | $-29.9M |
| Operating Income | $-5.4M -74.4% | $-3.1M -704.3% | $513.0K +103.6% | $-14.3M +62.4% | $-38.0M -29.9% | $-29.3M |
| EPS (Diluted) | $-28.58 +77.7% | $-128.37 -641750.0% | $-0.02 +95.9% | $-0.49 | — | — |
| Total Assets | $43.9M +10.5% | $39.7M -29.1% | $56.0M +4.4% | $53.7M +30.7% | $41.1M -18.3% | $50.3M |
| Total Debt | $10.1M | — | — | $147.0K -31.3% | $214.0K -60.3% | $539.0K |
| Operating Cash Flow | $-23.5M -177.2% | $-8.5M -109.4% | $-4.1M +67.2% | $-12.4M +67.9% | $-38.5M -264.4% | $-10.6M |
| Free Cash Flow | — | $-8.7M -112.8% | $-4.1M +66.9% | $-12.4M +67.9% | $-38.5M -264.4% | $-10.6M |
Get alerted when SONM's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for DNA X, Inc. including:
Top Institutional Holders of SONM
C2C Wealth Management, LLC
$182.8K35,500 shBlackRock, Inc.
$72.1K14,006 shCITADEL ADVISORS LLC
$65.1K12,740 shGEODE CAPITAL MANAGEMENT, LLC
$64.3K12,584 shVANGUARD CAPITAL MANAGEMENT LLC
$30.2K5,901 shVANGUARD FIDUCIARY TRUST CO
$23.0K4,496 shUBS Group AG
$11.9K2,304 shTower Research Capital LLC (TRC)
$3.3K642 shSBI Securities Co., Ltd.
$1.1K214 sh
| Fund | Value | Shares |
|---|---|---|
| C2C Wealth Management, LLC | $182.8K | 35,500 |
| BlackRock, Inc. | $72.1K | 14,006 |
| CITADEL ADVISORS LLC | $65.1K | 12,740 |
| GEODE CAPITAL MANAGEMENT, LLC | $64.3K | 12,584 |
| VANGUARD CAPITAL MANAGEMENT LLC | $30.2K | 5,901 |
| VANGUARD FIDUCIARY TRUST CO | $23.0K | 4,496 |
| UBS Group AG | $11.9K | 2,304 |
| Tower Research Capital LLC (TRC) | $3.3K | 642 |
| SBI Securities Co., Ltd. | $1.1K | 214 |
More Technology Companies
View all Technology →Put SONM on your watchlist
Track score changes the day DNA X, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SONM a good stock to buy?
13F Pro's AI-powered analysis of DNA X, Inc. (SONM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SONM are available on the SONM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SONM is classified as a small company.
Which hedge funds own SONM?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SONM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of DNA X, Inc.'s investment landscape.